Compugen Ltd. - (CGEN) closed at $2.10 on November 13, 2026, down 0.9% from the previous close, on volume of 208,861 shares (30-day average 226,231).
Data as of November 13, 2026.
13-Nov-2026
| # | Date | Strategy | Legs | Contracts |
|---|---|---|---|---|
| 1 | Nov 10, 2026 | Diagonal Call Spread | 18-Dec-26 : 19-Mar-272.5 : 5 C | 200 |
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 12, 2026. See the 10 largest for 30, 60 and 90 days
Oppenheimer Reaffirms Their Buy Rating on Compugen (CGEN)
TipRanks (Tue, 10-Nov 7:56 AM ET)
Stifel Nicolaus Remains a Buy on Compugen (CGEN)
TipRanks (Tue, 10-Nov 7:27 AM ET)
Compugen to Present UnigenX Platform at the 18th Annual PEGS Europe Summit
PRNewswire (Tue, 10-Nov 7:00 AM ET)
Compugen Reports Q3 Results as MAIA-Ovarian Trial Completes Enrollment
TipRanks (Mon, 9-Nov 7:33 AM ET)
Compugen Non-GAAP EPS of -$0.06 beats by $0.03, revenue of $3.8M beats by $2.83M
Seeking Alpha News (Mon, 9-Nov 7:12 AM ET)
Compugen Reports Third Quarter 2026 Results
PRNewswire (Mon, 9-Nov 7:00 AM ET)
Compugen to Participate in November Investor Conferences
PRNewswire (Tue, 3-Nov 7:00 AM ET)
Compugen to Release Third Quarter 2026 Results on Monday, November 9, 2026
PRNewswire (Mon, 26-Oct 7:00 AM ET)
PRNewswire (Tue, 6-Oct 7:00 AM ET)
PRNewswire (Tue, 22-Sep 7:00 AM ET)
Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing Unigen, its AI/ML-powered computational discovery capabilities, to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs: COM701, COM902, rilvegostomig, and GS-0321 (previously COM503), targeting immune checkpoints the company discovered computationally. The company's revenues are generated mainly from collaborative and license agreements. Geographically, it generates maximum revenue from the United Kingdom, and the rest from the United States.
Compugen Ltd. - trades on the NASDAQ stock market under the symbol CGEN.
As of November 13, 2026, CGEN stock price declined to $2.10 with 208,861 million shares trading.
CGEN has a beta of 1.66, meaning it tends to be more sensitive to market movements. CGEN has a correlation of 0.12 to the broad based SPY ETF.
CGEN has a market cap of $196.38 million. This is considered a Micro Cap stock.
Last quarter Compugen Ltd. - reported $4 million in Revenue and -$.06 earnings per share. This beat revenue expectation by $3 million and exceeded earnings estimates by $.03.
In the last 3 years, CGEN traded as high as $3.24 and as low as $.55.
The top ETF exchange traded funds that CGEN belongs to (by Net Assets): SPDW, AVDV, GWX, QQQS, AVSD.
CGEN has outperformed the market in the last year with a price return of +27.3% while the SPY ETF gained +13.4%. However, in the short term, CGEN had mixed performance relative to the market. It has underperformed in the last 3 months, returning -12.9% vs -2.8% return in SPY. But in the last 2 weeks, CGEN shares have fared better than the market returning +6.1% compared to SPY -0.2%.
CGEN support price is $2.04 and resistance is $2.21 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CGEN shares will trade within this expected range on the day.
